araag2/HINT huggingface dataset:
Clinical trial NCT02580591 (phase 3, status: completed)
Conditions: diabetes mellitus, type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: empagliflozin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Signed and dated written informed consent

          -  Male or female patient receiving insulin for the treatment of documented diagnosis of
             type 1 diabetes mellitus (T1DM) > 1 year

          -  C-peptide value of < 0.7 ng/mL

          -  Use of Multiple Daily Injections (MDI) of insulin or insulin pump user with total
             daily insulin >= 0.3 and <= 1.5 U/kg

          -  Glycated haemoglobin (HbA1c) >= 7.5% and <= 10.0%

          -  Good understanding of T1DM

          -  Age >= 18 years

          -  Body Mass Index (BMI) >= 18.5 kg/m2

          -  Estimated glomerular filtration rate >= 30 mL/min/1.73 m2

          -  Women of child-bearing potential must use highly effective methods of birth control

          -  Compliance with trial medication administration between 80% and 120% during placebo
             run-in period Further inclusion criteria apply

        Exclusion criteria:

          -  History of type 2 diabetes mellitus, maturity onset diabetes of the young (MODY),
             pancreatic surgery or chronic pancreatitis

          -  Pancreas, pancreatic islet cells or renal transplant recipient

          -  T1DM treatment with any other antihyperglycaemic drug except subcutaneous basal and
             bolus insulin within last 3 months

          -  Occurrence of severe hypoglycaemia within last 3 months and until randomisation

          -  Occurence of diabetic ketoacidosis within 3 months prior to Visit 1 and until Visit 6

          -  Irregular sleep/wake cycle

          -  Acute coronary syndrome, stroke or Transient Ischaemic Attack (TIA) within last 3
             months

          -  Severe gastroparesis

          -  Brittle diabetes

          -  Liver disease

          -  Eating disorders

          -  Treatment with anti-obesity drugs, weight-loss surgery or aggressive diet regimen

          -  Treatment with systemic corticosteroids

          -  Change in dose of thyroid hormones within last 6 weeks and until randomisation

          -  Cancer or treatment for cancer in the last five years

          -  Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells

          -  Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial

          -  Alcohol or drug abuse

          -  Intake of an investigational drug in another trial within last 30 days Further
             exclusion criteria apply
Clinical trial NCT02582632 (phase 3, status: completed)
Conditions: hepatitis c infection, hepatitis c virus
ICD codes: B17.0, B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ombitasvir/paritaprevir/ritonavir, dasabuvir
SMILES: [H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Chronic HCV infection at Screening.

          2. Screening laboratory result indicating HCV genotype 1b infection.

          3. Treatment-naïve and non-cirrhotic.

        Exclusion Criteria:

          1. HCV genotype or subtype other than GT1b.

          2. Positive test result for Hepatitis B surface antigen (HbsAg) or confirmed positive
             anti-HIV antibody (HIV Ab) test.

          3. Any current or past clinical evidence of cirrhosis.

          4. Screening laboratory analyses that shows abnormal results.

          5. Clinically significant abnormalities or co-morbidities, other than HCV infection that
             make the participant an unsuitable candidate for this study.
Clinical trial NCT02584504 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: alirocumab, placebo, atorvastatin, non-statin lipid-modifying therapy
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion criteria :

        Participants with hypercholesterolemia (heFH or non-FH) receiving non statin LMTs or the
        lowest strength of statin.

        Exclusion criteria:

          -  LDL-C <100 mg/dL (<2.59 mmol/L) at the screening visit (Week -3) in participants with
             heFH or in participants with non-FH who have a history of documented coronary heart
             disease.

          -  LDL-C <120 mg/dL (<3.10 mmol/L) at the screening visit (Week -3) in participants with
             non-FH participants who had a history of documented diseases or other risk factors
             classified as primary prevention category III as defined in JAS Guidelines for
             Prevention of Atherosclerotic Cardiovascular Diseases 2012.

          -  Not on a stable dose of LMT (including diet therapy alone) in the run-in period or the
             screening period.

          -  Fasting serum TGs >400 mg/dL (>4.52 mmol/L) at the screening period.

          -  Systolic blood pressure (BP) >160 mmHg or diastolic BP >100 mmHg at the run-in visit
             (Week -7) or the screening visit (Week -3) or the randomization visit (Week 0).

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT02585934 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: rvt-101, placebo
SMILES: O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subject with AD

          -  Ongoing donepezil therapy for AD

          -  An MMSE score 12 to 24 inclusive at Screening; MMSE score 10-26 inclusive at Baseline

          -  Hachinski Ischaemia score less than or equal to 4 at Screening.

          -  If female, subject must be: a. of non-childbearing potential or surgically sterile;
             or, b. willing to use an adequate methods of birth control. Male subjects who are
             sexually active will also be required to use an adequate form of birth control.

          -  Subject has the ability to comply with procedures for cognitive and other testing in
             the opinion of the investigator.

          -  Subject has a reliable caregiver who is willing to report on subject's status
             throughout the study.

        Exclusion Criteria:

        Other Causes for Dementia

          -  Diagnosis of vascular dementia

          -  Atypical clinical features or clinical course of dementia that would lead the
             investigator to conclude symptoms are more likely due to an alternate dementia
             diagnosis including, but not limited to, frontotemporal dementia, Lewy body dementia,
             or others.

        Confounding Medical Conditions

          -  History of significant psychiatric illness such as schizophrenia or bipolar affective
             disorder or any other significant psychiatric illness that in the opinion of the
             investigator would interfere with participation in the study;

          -  Any clinically relevant concomitant disease, which, in the opinion of the
             investigator, makes the subject unsuitable for inclusion in the study.
Clinical trial NCT02586025 (phase 3, status: active, not recruiting)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: fec chemotherapy, docetaxel, pertuzumab, placebo, trastuzumab
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed invasive breast carcinoma with a primary tumor size of more
             than (>) 2 centimeters (cm) by standard local assessment technique

          -  Breast cancer stage at presentation: early-stage (T2-3, N0-1, M0) or locally advanced
             (T2-3, N2 or N3, M0; T4, any N, M0)

          -  HER2-positive breast cancer confirmed by a Sponsor-designated central laboratory and
             defined as 3+ score by immunohistochemistry in > 10 percent (%) of immunoreactive
             cells or HER2 gene amplification (ratio of HER2 gene signals to centromere 17 signals
             equal to or more than [>=] 2.0) by in situ hybridization

          -  Known hormone receptor status (estrogen receptor and/or progesterone receptor)

          -  Eastern Cooperative Oncology Group Performance Status equal to or less than (<=) 1

          -  Baseline left ventricular ejection fracture >= 55% measured by echocardiography
             (preferred) or multiple gated acquisition scan

          -  Negative serum pregnancy test

        Exclusion Criteria:

          -  Stage IV metastatic breast cancer

          -  Inflammatory breast cancer

          -  Previous anti-cancer therapy or radiotherapy for any malignancy

          -  History of other malignancy within 5 years prior to screening, except for
             appropriately-treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or
             Stage I uterine cancer

          -  Concurrent anti-cancer treatment in another investigational trial, including hormone
             therapy, bisphosphonate therapy, or immunotherapy

          -  Major surgical procedure unrelated to breast cancer within 4 weeks prior to
             randomization or from which the participant has not fully recovered

          -  Serious cardiac illness or medical condition

          -  Other concurrent serious diseases that may interfere with planned treatment, including
             severe pulmonary conditions/illness

          -  Any abnormalities in liver, kidney or hematologic function laboratory tests
             immediately prior to randomization

          -  Sensitivity to any of the study medications, any of the ingredients or excipients of
             these medications, or benzyl alcohol

          -  Pregnant or lactating
Clinical trial NCT02594332 (phase 3, status: terminated)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: mepolizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    recruitment problems
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients must be able to give written informed consent prior to participation in the
             study, which will include the ability to comply with the requirements and restrictions
             listed in the consent form.

          2. Male or female patients at least 18 years

          3. Physician-diagnosis of asthma and evidence of asthma as documented by either
             reversibility of airflow obstruction (FEV1 ≥ 12% or 200 ml) demonstrated at visit 1 or
             visit 2 .

          4. ICS dose must be ≥ 1000 μg/day BDP or equivalent daily with or without maintenance
             oral corticosteroids.

          5. Treatment in the past 12 months with an additional controller medication for at least
             3 successive months, e.g., long-acting beta-2-agonist (LABA), leukotriene receptor
             antagonist (LTRA), or theophylline.

          6. Persistent airflow obstruction as indicated by a pre-bronchodilator FEV1 < 80%
             predicted recorded at Visit 1 or < 90% for patients on oral corticosteroids.

          7. An elevated peripheral blood eosinophil level of ≥ 300/µL that is related to asthma or
             ≥ 150/µL in patients treated with oral corticosteroids as maintenance therapy
             demonstrated at visit 1 or in the previous 12 months

          8. Confirmed history of two or more exacerbations requiring treatment with systemic
             corticosteroids (intramuscular, intravenous, or oral), in the 12 months prior to visit
             1, despite the use of high-dose inhaled corticosteroids. For patients receiving
             maintenance corticosteroids, the corticosteroid treatment for the exacerbations must
             have been a two-fold increase or greater in the dose.

        Exclusion Criteria:

          1. Current smokers or former smokers with a smoking history of ≥ 10 pack years (number of
             pack years = (number of cigarettes per day / 20) x number of years smoked). Patients
             who have not smoked for ≥ 6 months before visit 1 and have < 10 pack years can be
             included into the study.

          2. Presence of a clinically important lung condition other than asthma. This includes
             current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis,
             or diagnoses of emphysema or chronic bronchitis (chronic obstructive pulmonary disease
             other than asthma) or a history of lung cancer.

          3. Patients who have received omalizumab [Xolair] within 130 days of Visit 1.

          4. Patients who have received any biological to treat inflammatory disease within 5
             half-lives of visit 1
Clinical trial NCT02596334 (phase 3, status: terminated)
Conditions: hiv
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: dolutegravir 50mg +abacavir 600mg +lamivudine 300mg, dolutegravir
SMILES: N[C@@H](CO)C(O)=O, N[C@@H](CO)C(O)=O
Reason stopped: 
    5 patients on tivicay had virological failure
  
Eligibility criteria:

        Inclusion Criteria:

          -  HIV-1-infected patients with no previous AIDS event (excluding a healed tuberculosis);

          -  Current antiretroviral treatment associating dolutegravir + abacavir + lamivudine for
             at least 1 month;

          -  Nadir CD4 ≥ 100/mm3;

          -  Plasma RNA viral load < 50 copies/ml for at least 12 months;

          -  Plasma RNA viral load <20 or 40 copies/ml (according to the threshold of the method
             used by local laboratory) at the screening visit;

          -  No documented virologic failure or known resistance to any integrase inhibitor,

          -  Patient having provided a written consent;

          -  Patients follow-up possible in ambulatory;

          -  Patient age > 18 years;

          -  Covered by health insurance

        Exclusion Criteria:

          -  Non-compliant patient

               -  Subject is pregnant, or lactating, or of childbearing potential and without
                  contraception;

               -  Active opportunistic infections (defining AIDS);

               -  Known hypersensibility to abacavir or lamivudine or dolutegravir;

               -  Patients harboring HLA B*5701;

               -  Major overweight (BMI ≥ 40);

               -  Weight <40 kg;

               -  Creatinine clearance < 50ml/min;

               -  Cirrhosis or severe liver failure (factor V < 50%);

               -  Life Prognosis threatened within 6 months;

               -  Circumstances that may impair judgment or understanding of the information given
                  to the patient;

               -  Co-medication with carbamazepin, oxcarbamazepin, fosphenytoïn, phenobarbital,
                  phenytoïn, primidon, St John's wort or dofetilid;

               -  Malabsorption syndromes;

               -  The following laboratory criteria:

                    -  Serum AST,ALT > 5 x upper limit of normal (ULN)

                    -  Thrombocytopenia with platelet count < 50.000/ml

                    -  Anemia with hemoglobin < 8g/dl

                    -  Polynuclear neutrophil count < 500/mm3
Clinical trial NCT02596893 (phase 3, status: terminated)
Conditions: crohn disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: ged-0301, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Subjects must satisfy the following criteria to be enrolled in the study:

          -  Male or female ≥ 18 years

          -  Active Crohn's disease (CD) disease as determined by the Crohn's Disease Activity
             Index (CDAI) score and the Simple Endoscopic Score for Crohn's Disease (SES-CD)

          -  Must meet a determined average minimum number of daily stools or rating of abdominal
             pain over a 7 day period

          -  Subject must have failed or experienced intolerance to at least one of the following:
             budesonide; systemic corticosteroids; immunosuppressants (eg, azathiopurine,
             6-mercaptopurine, or methotrexate); or biologics for the treatment of CD.

        Exclusion Criteria:

        The presence of any of the following will exclude a subject from enrollment:

          -  Diagnosis of ulcerative colitis (UC), indeterminate colitis, ischemic colitis,
             microscopic colitis, radiation colitis or diverticular disease-associated colitis

          -  Local manifestations of Crohn's Disease (CD) such as symptomatic/severe strictures,
             abscesses, short bowel syndrome; or other disease complications for which surgery
             might be indicated or could confound the evaluation of efficacy

          -  Intestinal resection within 6 months or any intra-abdominal surgery within 3 months
             prior to the Screening Visit

          -  Ileostomy or a colostomy

          -  Subject has a history of any clinically significant medical condition that, in the
             investigator's opinion, would prevent the subject from participating in the study.
Clinical trial NCT02597933 (phase 3, status: completed)
Conditions: scleroderma, systemic
ICD codes: L94.1, L94.0
Drugs: nintedanib, placebo
SMILES: COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Age >= 18 years

          -  2013 American College of Rheumatology (ACR) / EULAR classification criteria for SSc
             fulfilled

          -  SSc disease onset (defined by first non-Raynaud symptom) within 7 years

          -  SSc related Interstitial Lung Disease confirmed by High Resolution Computer Tomography
             (HRCT); Extent of fibrotic disease in the lung >= 10%

          -  FVC >= 40% of predicted normal

          -  Carbon Monoxide Diffusion Capacity (DLCO) 30% to 89% of predicted normal

        Exclusion criteria:

          -  Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) >1.5 x ULN

          -  Bilirubin >1.5 x ULN

          -  Creatinine clearance <30 mL/min

          -  Airway obstruction (pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1)/FVC
             <0.7)

          -  Other clinically significant pulmonary abnormalities

          -  Significant Pulmonary Hypertension (PH)

          -  Cardiovascular diseases

          -  More than 3 digital fingertip ulcers or a history of severe digital necrosis requiring
             hospitalization or severe other ulcers

          -  Bleeding risk (such as predisposition to bleeding, fibrinolysis, full-dose
             anticoagulation, high dose antiplatelet therapy, history of hemorrhagic central
             nervous system (CNS) event within last year

          -  international normalised ratio (INR) >2, prolongation of prothrombin time (PT) and
             partial thromboplastin time (PTT) by >1.5 x ULN)

          -  History of thrombotic event within last year

          -  Clinical signs of malabsorption or needing parenteral nutrition

          -  Previous treatment with nintedanib or pirfenidone

          -  Treatment with prednisone >10 mg/day, azathioprine, hydroxychloroquine, colchicine,
             D-penicillamine, sulfasalazine, cyclophosphamide, rituximab, tocilizumab, abatacept,
             leflunomide, tacrolimus, newer anti-arthritic treatments like tofacitinib and
             cyclosporine A, potassium para-aminobenzoate

          -  Unstable background therapy with either mycophenolate mofetil or methotrexate

          -  Previous or planned hematopoietic stem cell transplantation

          -  Patients with underlying chronic liver disease (Child Pugh A, B, C hepatic impairment)
Clinical trial NCT02600325 (phase 3, status: completed)
Conditions: acute hepatitis c, human immunodeficiency virus, hepatitis c
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4, B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: grazoprevir/elbasvir 100mg/50mg
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CNC(=N3)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. HIV positive

          2. Acute HCV genotype 1 or 4 infection (≤26 weeks old at the baseline visit)

        Exclusion Criteria:

          1. Not on cART and a CD4 <500 at the time of screening

          2. Patients on cART for >6 months with a HIV viral load >400 copies

          3. Disallowed co-medication that cannot be stopped or replaced

          4. History of liver cirrhosis of any etiology. Inclusion of patients with a chronic
             well-controlled HBV (HBV-DNA <below the limit of detection) is allowed if fibroscan
             excludes >F1 fibrosis

          5. Protease inhibitor based and NNRTI based cART regimens are not allowed. Therefore, the
             inability to switch to a HAART regimen consisting of 2 nucleoside/tide reverse
             transcriptase inhibitors and an allowed third agent which can be raltegravir
             (Isentress®) 400mg BID, dolutegravir (Tivicay) 50mg QD or rilpivirine 25mg QD.
Clinical trial NCT02600351 (phase 3, status: terminated)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ldv/sof, rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Reason stopped: 
    due to lack of feasibility of enrolling participants, the study was terminated early.
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  HCV RNA > 15 IU/mL at screening

          -  HCV genotype 1 or 4

          -  Chronic HCV infection (≥ 6 months)

          -  Prior virologic failure after treatment with SOF in combination with simeprevir (SMV)
             ± RBV or with RBV ± pegylated interferon (PEG)

          -  Cirrhotic and non-cirrhotic as determined by standard methods

          -  Male and female individuals of childbearing potential who engage in heterosexual
             intercourse must agree to use protocol specified method(s) of contraception

        Key Exclusion Criteria:

          -  Prior exposure to approved or experimental non-structural protein (NS5A) inhibitors

          -  Prior exposure to nucleos(t)ide polymerase inhibitors, other than SOF

          -  Pregnant or nursing female or male with pregnant female partner

          -  Coinfection with HIV or hepatitis B virus

          -  Current or prior history of clinical hepatic decompensation

          -  Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin
             cancers)

          -  Chronic use of systemic immunosuppressive agents

          -  History of clinically significant illness or any other medical disorder that may
             interfere with individual's treatment, assessment or compliance with the protocol

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.